Vivodyne lands $38m to transform drug development with lab-grown human organs
Vivodyne, a biotech company focused on developing more effective drugs tested on lab-grown human organs, announced a colossal close of $38 million in total seed financing. The funding round, led by Khosla Ventures, included contributions from Kairos Ventures, CS Ventures, MBX Capital, and Bison Ventures. This financial boost marks a new era in drug discovery, leveraging Vivodyne’s clinically predictive AI stack to identify novel therapeutic targets and predict patient responses to new drugs.
Advancing Drug Discovery with Lab-Grown Human Organ Tissues
Vivodyne’s approach transforms drug discovery by testing on over 20 types of bioengineered human organ tissues that accurately mimic human physiology. This breakthrough promises to capture the effects of new therapies and predict patient outcomes effectively, revolutionizing the pharmaceutical industry. The company’s platform can cultivate, dose, and analyze over 10,000 individual human tissues simultaneously, producing extensive human datasets that power the next generation of AI for drug discovery.
Revolution in biotech: Vivodyne secures $38m for AI-driven drug discovery with lab-grown human organs
Bridging the Gap in AI-Driven Drug Development
One of the significant challenges in drug development is obtaining realistic, scalable, and reproducible human-predictive data. Vivodyne’s unique method overcomes this obstacle by generating patient-level human results even before clinical trial testing. This innovation is pivotal in enhancing the predictive accuracy of AI in drug development and improving the success rates of AI-generated drugs.
The Future of Therapeutics Development
Vivodyne’s platform stands out for its seamless integration of lifelike lab-grown human tissues, cutting-edge robotics, and a robust AI stack. The focus on generating vast volumes of predictive, preclinical human data is a game-changer, offering a promising future for therapeutics development. The company’s collaborations with top pharma companies and its technology’s potential to create better and safer drugs quickly set a new standard in the field.